MA27666A1 - Procede de purification - Google Patents
Procede de purificationInfo
- Publication number
- MA27666A1 MA27666A1 MA28487A MA28487A MA27666A1 MA 27666 A1 MA27666 A1 MA 27666A1 MA 28487 A MA28487 A MA 28487A MA 28487 A MA28487 A MA 28487A MA 27666 A1 MA27666 A1 MA 27666A1
- Authority
- MA
- Morocco
- Prior art keywords
- cytolysin
- purification process
- detergent
- binding
- salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La présente invention porte sur un procédé de purification de cytolysines bactériennes telles que la pneumolysine pneumococcique. Une étape unique de chromatographie permet d'effectuer une excellente purification de la cytolysine en liant la cytolysine soluble agrégée à un matériau chromatographique à interaction hydrophobe en présence de détergent et d'une forte quantité de sel.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0305792A GB0305792D0 (en) | 2003-03-13 | 2003-03-13 | Purification Process |
GB0305791A GB0305791D0 (en) | 2003-03-13 | 2003-03-13 | Detoxification process |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27666A1 true MA27666A1 (fr) | 2005-12-01 |
Family
ID=32992596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28487A MA27666A1 (fr) | 2003-03-13 | 2005-09-09 | Procede de purification |
Country Status (23)
Country | Link |
---|---|
US (3) | US8084235B2 (fr) |
EP (1) | EP1601689B1 (fr) |
JP (2) | JP4597123B2 (fr) |
KR (1) | KR101052996B1 (fr) |
CN (1) | CN101818185B (fr) |
AU (2) | AU2004219910B2 (fr) |
BR (1) | BRPI0408094A (fr) |
CA (2) | CA2518669C (fr) |
CY (1) | CY1107134T1 (fr) |
DE (1) | DE602004010376T2 (fr) |
DK (1) | DK1601689T3 (fr) |
EG (1) | EG24449A (fr) |
ES (1) | ES2295836T3 (fr) |
HK (1) | HK1086013A1 (fr) |
IL (1) | IL210984A0 (fr) |
IS (1) | IS2587B (fr) |
MA (1) | MA27666A1 (fr) |
MX (1) | MXPA05009579A (fr) |
NO (1) | NO336672B1 (fr) |
NZ (1) | NZ541969A (fr) |
PT (1) | PT1601689E (fr) |
RU (1) | RU2340627C2 (fr) |
WO (1) | WO2004081515A2 (fr) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101818185B (zh) | 2003-03-13 | 2016-05-25 | 葛兰素史密丝克莱恩生物有限公司 | 纯化细菌溶细胞素的方法 |
GB0421083D0 (en) * | 2004-09-22 | 2004-10-27 | Glaxosmithkline Biolog Sa | Purification process |
EP1863502B1 (fr) | 2005-03-23 | 2018-09-12 | Sonoma Pharmaceuticals, Inc. | Methode permettant de traiter les ulceres de la peau a l'aide d'une solution aqueuse a potentiel d'oxydoreduction |
EP1896062B1 (fr) | 2005-06-27 | 2010-03-31 | GlaxoSmithKline Biologicals S.A. | Composition immunogène |
NO346529B1 (no) | 2005-12-22 | 2022-09-26 | Glaxosmithkline Biologicals Sa | Bruk av et immunogenpreparat for småbarn, omfattende 22F sakkaridkonjugat |
GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
CA2637197C (fr) | 2006-01-20 | 2017-01-31 | Oculus Innovative Sciences, Inc. | Procedes destines a traiter ou a prevenir une peritonite avec une solution aqueuse a potentiel d'oxydo-reduction |
PL2066344T3 (pl) | 2006-09-07 | 2011-10-31 | Glaxosmithkline Biologicals Sa | Skojarzona szczepionka zawierająca inaktywowany wirus polio |
RU2487890C2 (ru) * | 2007-04-16 | 2013-07-20 | МинерваКС Апс | Слитый белок, способный индуцировать защитный иммунитет против стрептококка группы в, и вакцина, содержащая такой белок |
EP2142211A1 (fr) | 2007-05-02 | 2010-01-13 | GlaxoSmithKline Biologicals S.A. | Vaccin |
SI2167121T1 (sl) | 2007-06-26 | 2015-12-31 | Glaxosmithkline Biologicals S.A. | Cepivo, ki obsega kapsularne polisaharidne konjugate Streptococcusa pneumoniae |
KR20110009157A (ko) | 2008-04-16 | 2011-01-27 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
AU2009286769A1 (en) * | 2008-08-28 | 2010-03-04 | Glaxosmithkline Biologicals S.A. | Vaccine |
EP2424562B1 (fr) | 2009-04-30 | 2015-10-07 | Coley Pharmaceutical Group, Inc. | Vaccin pneumococcique et ses utilisations |
US8668911B2 (en) | 2009-05-14 | 2014-03-11 | The Regents Of The University Of Michigan | Streptococcus vaccine compositions and methods of using the same |
KR101781229B1 (ko) | 2009-06-15 | 2017-09-22 | 오클루스 이노바티브 사이언시즈 인코포레이티드 | 차아염소산을 함유하는 용액 및 그의 사용 방법 |
PT2473605T (pt) | 2009-09-03 | 2018-05-28 | Pfizer Vaccines Llc | Vacina pcsk9 |
HUE034251T2 (en) | 2009-10-30 | 2018-02-28 | Glaxosmithkline Biologicals Sa | Purification of type 5 and type 8 capsular saccharides from Staphylococcus aureus |
GB201003924D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Immunogenic composition |
WO2012131504A1 (fr) | 2011-03-02 | 2012-10-04 | Pfizer Inc. | Vaccin à base de pcsk9 |
ES2742823T3 (es) * | 2011-04-22 | 2020-02-17 | Wyeth Llc | Composiciones relacionadas con una toxina mutante de Clostridium difficile y sus procedimientos |
AR086405A1 (es) | 2011-05-17 | 2013-12-11 | Glaxosmithkline Biolog Sa | Vacuna de streptococcus pneumoniae |
ES2763415T3 (es) | 2012-09-19 | 2020-05-28 | Univ Osaka | Vacuna neumocócica que contiene proteína A superficial neumocócica |
AU2013352723B2 (en) * | 2012-11-30 | 2017-01-05 | Bioneer Corporation | Apparatus for automatically preparing cell-free proteins and method for preparing proteins using same |
WO2015095868A1 (fr) | 2013-12-20 | 2015-06-25 | Wake Forest University Health Sciences | Méthodes et compositions permettant d'augmenter les taux d'anticorps protecteurs induits par des vaccins antipneumococciques polyosidiques |
ES2820824T3 (es) | 2014-01-21 | 2021-04-22 | Pfizer | Composiciones inmunogénicas que comprenden antígenos sacáridos capsulares conjugados y usos de las mismas |
HRP20231504T1 (hr) | 2014-01-21 | 2024-03-01 | Pfizer Inc. | Polisaharidi kapsule iz bakterije streptococcus pneumoniae i njihovi konjugati |
US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
PT3096783T (pt) | 2014-01-21 | 2021-08-16 | Pfizer | Polissacáridos capsulares de streptococcus pneumoniae e conjugados dos mesmos |
ES2930318T3 (es) | 2014-02-14 | 2022-12-09 | Pfizer | Conjugados glucoproteicos inmunogénicos |
BR112017013891B1 (pt) | 2015-01-15 | 2024-01-30 | Pfizer Inc | Composições imunogênicas para uso em vacinas pneumocócicas |
US9218427B1 (en) * | 2015-01-21 | 2015-12-22 | Maana, Inc. | Dynamic semantic models having multiple indices |
WO2016168815A1 (fr) * | 2015-04-16 | 2016-10-20 | Iventprise LLC | Compositions de vaccin immunogène à base de bordetella pertussis |
TWI720448B (zh) | 2015-07-21 | 2021-03-01 | 美商輝瑞股份有限公司 | 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途 |
GB201518684D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
US10786561B2 (en) | 2015-11-20 | 2020-09-29 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
GB201603029D0 (en) * | 2016-02-22 | 2016-04-06 | Glaxosmithkline Biolog Sa | Vaccine |
EA039427B1 (ru) | 2016-08-05 | 2022-01-26 | Санофи Пастер Инк. | Поливалентная пневмококковая полисахаридно-белковая конъюгатная композиция |
KR102437120B1 (ko) | 2016-08-05 | 2022-08-25 | 사노피 파스퇴르 인코포레이티드 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
US20190360013A1 (en) * | 2016-12-02 | 2019-11-28 | President And Fellows Of Harvard College | Processive Template Independent DNA Polymerase Variants |
CN110366428B (zh) | 2016-12-30 | 2024-05-17 | Vaxcyte公司 | 具有非天然氨基酸的多肽-抗原缀合物 |
US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
EP3570879B1 (fr) | 2017-01-20 | 2022-03-30 | Pfizer Inc. | Composition immunogène pour l'utilisation dans vaccin pneumococcique |
KR102650073B1 (ko) | 2017-01-31 | 2024-03-20 | 머크 샤프 앤드 돔 엘엘씨 | 스트렙토코커스 뉴모니아 혈청형 19f 유래의 협막 다당류 단백질 접합체의 제조 방법 |
US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
AU2018280272C1 (en) | 2017-06-10 | 2021-05-06 | Inventprise, Inc. | Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity |
CA3074708A1 (fr) | 2017-09-07 | 2019-03-14 | Merck Sharp & Dohme Corp. | Polysaccharides antipneumococciques et leur utilisation dans des conjugues immunogenes polysaccharide-proteine porteuse |
CA3084436A1 (fr) | 2017-12-06 | 2019-07-18 | Merck Sharp & Dohme Corp. | Compositions comprenant des conjugues polysaccharide-proteine de streptococcus pneumoniae et leurs methodes d'utilisation |
EP3749358A4 (fr) | 2018-02-05 | 2022-04-20 | Sanofi Pasteur, Inc. | Composition de conjugué polysaccharide-protéine pneumococcique multivalent |
KR102486891B1 (ko) | 2018-02-05 | 2023-01-10 | 사노피 파스퇴르 인코포레이티드 | 다가 폐렴구균성 다당류-단백질 접합체 조성물 |
CA3096358A1 (fr) | 2018-04-18 | 2019-10-24 | Sk Bioscience Co., Ltd. | Polysaccharides capsulaires de streptococcus pneumoniae et conjugues immunogenes de ceux-ci |
US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
JP2022512345A (ja) | 2018-12-12 | 2022-02-03 | ファイザー・インク | 免疫原性多重ヘテロ抗原多糖-タンパク質コンジュゲートおよびその使用 |
JP2022513458A (ja) | 2018-12-12 | 2022-02-08 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | O-結合型グリコシル化のための修飾キャリアタンパク質 |
EP3897705A2 (fr) | 2018-12-19 | 2021-10-27 | Merck Sharp & Dohme Corp. | Compositions comprenant des conjugués polysaccharide-protéine de streptococcus pneumoniae et leurs méthodes d'utilisation |
JP7239509B6 (ja) | 2019-02-22 | 2023-03-28 | ファイザー・インク | 細菌多糖類を精製するための方法 |
WO2020208502A1 (fr) | 2019-04-10 | 2020-10-15 | Pfizer Inc. | Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués, kits les comprenant et leurs utilisations |
MX2022001241A (es) | 2019-07-31 | 2022-04-20 | Sanofi Pasteur Inc | Composiciones de conjugados neumococicos multivalentes polisacarido - proteina y metodos para usar los mismos. |
US20230000966A1 (en) | 2019-11-01 | 2023-01-05 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
CA3171864A1 (fr) | 2020-02-21 | 2021-08-26 | Pfizer Inc. | Purification de saccharides |
BR112022014555A2 (pt) | 2020-02-23 | 2022-09-20 | Pfizer | Composições de escherichia coli e métodos das mesmas. |
EP4232593A1 (fr) | 2020-10-22 | 2023-08-30 | Pfizer Inc. | Procédés de purification de polysaccharides bactériens |
MX2023004912A (es) | 2020-10-27 | 2023-05-16 | Pfizer | Composiciones de escherichia coli y metodos de las mismas. |
MX2023005221A (es) | 2020-11-04 | 2023-05-16 | Pfizer | Composiciones inmunogenicas para uso en vacunas neumococicas. |
US20220202923A1 (en) | 2020-12-23 | 2022-06-30 | Pfizer Inc. | E. coli fimh mutants and uses thereof |
TW202245835A (zh) | 2021-02-04 | 2022-12-01 | 美商默沙東有限責任公司 | 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物 |
WO2022234405A1 (fr) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination contre des infections bactériennes et à betacoronavirus |
WO2022234416A1 (fr) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination contre des infections à pneumocoque et à covid-19 |
CA3221074A1 (fr) | 2021-05-28 | 2022-12-01 | Pfizer Inc. | Compositions immunogenes comprenant des antigenes saccharidiques capsulaires conjugues et leurs utilisations |
EP4346893A2 (fr) | 2021-05-28 | 2024-04-10 | Pfizer Inc. | Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations |
WO2023135515A1 (fr) | 2022-01-13 | 2023-07-20 | Pfizer Inc. | Compositions immunogènes à base d'antigènes saccharidiques capsulaires conjugués et leurs utilisations |
WO2023161817A1 (fr) | 2022-02-25 | 2023-08-31 | Pfizer Inc. | Procédés d'incorporation de groupes azido dans des polysaccharides capsulaires bactériens |
WO2023218322A1 (fr) | 2022-05-11 | 2023-11-16 | Pfizer Inc. | Procédé de production de formulations de vaccin avec des conservateurs |
WO2024084397A1 (fr) | 2022-10-19 | 2024-04-25 | Pfizer Inc. | Vaccination contre infections à pneumocoques et à covid-19 |
WO2024110827A1 (fr) | 2022-11-21 | 2024-05-30 | Pfizer Inc. | Procédés de préparation d'antigènes saccharidiques capsulaires conjugués et leurs utilisations |
US20240181028A1 (en) | 2022-11-22 | 2024-06-06 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
WO2024116096A1 (fr) | 2022-12-01 | 2024-06-06 | Pfizer Inc. | Formulations de vaccin pneumococcique conjugué |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8807860D0 (en) * | 1988-04-05 | 1988-05-05 | Connaught Lab | Pertussis vaccine |
JP3237842B2 (ja) | 1988-12-16 | 2001-12-10 | オランダ国 | ニューモリシンミュータント及びそれから製造されたニューモコッカルワクチン |
DE4133707A1 (de) * | 1991-10-11 | 1993-04-15 | Behringwerke Ag | Verfahren zur reinigung von streptolysin o, intaktes streptolysin o erhaeltlich nach diesem verfahren und seine verwendung |
GB9216351D0 (en) * | 1992-07-31 | 1992-09-16 | Wellcome Found | Vaccine production |
US5565204A (en) | 1994-08-24 | 1996-10-15 | American Cyanamid Company | Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections |
BR9606987A (pt) * | 1995-01-27 | 1997-11-04 | Genencor Int | Processos para a recuperação de um produto de fermentação desejado a preparação de um pó detergente |
US5877298A (en) * | 1995-05-04 | 1999-03-02 | Connaught Lab | Acellular pertussis vaccines and methods of preparing thereof |
US5667786A (en) * | 1995-06-07 | 1997-09-16 | Novavax, Inc. | Method for treating tumors with a toxin |
KR100619350B1 (ko) * | 1997-07-21 | 2006-09-05 | 박스터 헬쓰케어 에스.에이. | 변형 면역성 뉴멀리신 백신조성물 |
EP1162999B1 (fr) * | 1999-03-19 | 2006-11-29 | Glaxosmithkline Biologicals S.A. | Vaccin contre Streptococcus pneumoniae |
JP4132694B2 (ja) * | 2000-03-10 | 2008-08-13 | 独立行政法人科学技術振興機構 | 受容体認識部位が保存された生理活性物質の誘導体及びその使用方法 |
GB0022742D0 (en) * | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
CN101818185B (zh) | 2003-03-13 | 2016-05-25 | 葛兰素史密丝克莱恩生物有限公司 | 纯化细菌溶细胞素的方法 |
GB0421083D0 (en) | 2004-09-22 | 2004-10-27 | Glaxosmithkline Biolog Sa | Purification process |
-
2004
- 2004-03-11 CN CN201010157455.6A patent/CN101818185B/zh not_active Expired - Fee Related
- 2004-03-11 CA CA2518669A patent/CA2518669C/fr not_active Expired - Fee Related
- 2004-03-11 ES ES04719447T patent/ES2295836T3/es not_active Expired - Lifetime
- 2004-03-11 BR BRPI0408094-7A patent/BRPI0408094A/pt not_active Application Discontinuation
- 2004-03-11 PT PT04719447T patent/PT1601689E/pt unknown
- 2004-03-11 NZ NZ541969A patent/NZ541969A/en not_active IP Right Cessation
- 2004-03-11 DK DK04719447T patent/DK1601689T3/da active
- 2004-03-11 EP EP04719447A patent/EP1601689B1/fr not_active Expired - Lifetime
- 2004-03-11 CA CA2812817A patent/CA2812817C/fr not_active Expired - Fee Related
- 2004-03-11 MX MXPA05009579A patent/MXPA05009579A/es active IP Right Grant
- 2004-03-11 JP JP2006504684A patent/JP4597123B2/ja not_active Expired - Fee Related
- 2004-03-11 WO PCT/EP2004/002641 patent/WO2004081515A2/fr active Application Filing
- 2004-03-11 AU AU2004219910A patent/AU2004219910B2/en not_active Ceased
- 2004-03-11 KR KR1020057017163A patent/KR101052996B1/ko not_active IP Right Cessation
- 2004-03-11 RU RU2005125832/13A patent/RU2340627C2/ru not_active IP Right Cessation
- 2004-03-11 DE DE602004010376T patent/DE602004010376T2/de not_active Expired - Lifetime
- 2004-03-11 US US10/549,064 patent/US8084235B2/en not_active Expired - Fee Related
-
2005
- 2005-08-18 IS IS7993A patent/IS2587B/is unknown
- 2005-08-22 EG EGNA2005000491 patent/EG24449A/xx active
- 2005-09-06 NO NO20054134A patent/NO336672B1/no not_active IP Right Cessation
- 2005-09-09 MA MA28487A patent/MA27666A1/fr unknown
-
2006
- 2006-05-24 HK HK06105983.2A patent/HK1086013A1/xx not_active IP Right Cessation
-
2008
- 2008-01-10 CY CY20081100036T patent/CY1107134T1/el unknown
-
2010
- 2010-08-10 AU AU2010212257A patent/AU2010212257B2/en not_active Ceased
- 2010-08-11 JP JP2010180165A patent/JP5683866B2/ja not_active Expired - Fee Related
-
2011
- 2011-02-01 IL IL210984A patent/IL210984A0/en unknown
- 2011-08-31 US US13/222,066 patent/US8309327B2/en not_active Expired - Fee Related
-
2012
- 2012-09-27 US US13/628,632 patent/US8815254B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27666A1 (fr) | Procede de purification | |
ATE425989T1 (de) | Proteinreinigungsverfahren | |
SE9803838D0 (sv) | A chromatography method and a column material useful in said method | |
EA200401198A1 (ru) | АНТИТЕЛА ПРОТИВ αvβ6 | |
EA201170648A1 (ru) | Очистка спиртов перед их применением в присутствии кислотного катализатора | |
BRPI0605382A (pt) | processo para preparação de 1-buteno a partir de misturas industriais de hidrocarbonetos-c4 | |
NO971684D0 (no) | Nye benzoxazoler | |
CA2157905A1 (fr) | Procede de purification des taxoides | |
DE602005013263D1 (de) | Reinigung von glykopeptiden | |
ATE307649T1 (de) | Kontinuierliches verfahren zur trennung von stoffen nach molekülgrösse | |
EA200500311A1 (ru) | Производство олефинов | |
FR2858410B1 (fr) | Procede de determination des contraintes, deformations, endommagement de pieces constituees d'un materiau solide. | |
WO2009003952A3 (fr) | Colonne et procédé de préparation d'un échantillon biologique pour profiler une protéine | |
FI973433A (fi) | Menetelmä alkoholien tislaamiseksi | |
DE602004013040D1 (de) | Aufreinigung von immunglobulinen | |
DK0943010T3 (da) | Fremgangsmåde til påvisning af levende mikrobiologiske kontaminanter i en prøve af et levnedsmiddelprodukt | |
ATE233725T1 (de) | Verfahren zum herstellen von methylmethacrylat | |
ATE300516T1 (de) | Derivatisierung von trägeroberflächen | |
WO2003010278A3 (fr) | Procede automatise destine a detecter des organismes pathogenes dans l'eau | |
DK1404844T3 (da) | Fremgangsmåde til fremstilling af 2,4-dideoxyhexoser og 2,4,6-trideoxyhyxoser | |
FR2889078B1 (fr) | Nouvelle methode de chromatographie d'affinite d'antithrombine iii | |
EA199700235A1 (ru) | Способ получения ингибитора протеазы вич из (2-s)-4-пиколил-2-пиперазин-трет-бутилкарбоксамида | |
ATE294466T1 (de) | Zeitanpassung in einem cdma-system | |
FR2660579B1 (fr) | Procede de broyage de matieres premieres solides, tels que des minerais. | |
BR9909570A (pt) | Processo altamente seletivo, produto preparado pelo mesmo, e, processo para preparar uma quinonaimina a partir de uma hidroxifenilamina correspondente |